Multivariate Cox regression models, entire study cohort (n = 253)
| . | Overall mortality . | Failure for DFS . | Relapse . |
|---|---|---|---|
| MRD status | |||
| Negative (n = 199) | 1 (reference) | 1 (reference) | 1 (Reference) |
| Positive (n = 54) | 2.61 (1.62-4.20); P < .001 | 3.74 (2.38-5.87); P < .001 | 4.90 (2.87-8.37); P < .001 |
| Age (per 10 y) | 1.05 (0.90-1.22); P = NS | 1.07 (0.94-1.23); P = NS | 1.02 (0.87-1.21); P = NS |
| CR status | |||
| CR1 (n = 183) | 1 (reference) | 1 (reference) | 1 (reference) |
| CR2 (n = 70) | 1.01 (0.54-1.92); P = NS | 1.22 (0.69-2.17); P = NS | 1.15 (0.58-2.31); P = NS |
| Cytogenetic risk group | |||
| Intermediate/favorable (n = 190) | 1 (reference) | 1 (reference) | 1 (reference) |
| Adverse (n = 56) | 1.41 (0.78-2.54); P = NS | 1.50 (0.88-2.57); P = NS | 1.61 (0.83-3.13); P = NS |
| Type of AML | |||
| Primary AML (n = 184) | 1 (reference) | 1 (reference) | 1 (reference) |
| Secondary AML (n = 69) | 1.24 (0.74-2.09); P = NS | 1.29 (0.80-2.07); P = NS | 1.06 (0.59-1.92); P = NS |
| Number of induction/re-induction courses before HCT* | 1.21 (0.83-1.77); P = NS | 1.45 (1.04-2.01); P = .03 | 1.53 (1.03-2.27); P = .04 |
| Consolidation before HCT | |||
| No (n = 82) | 1 (reference) | 1 (reference) | 1 (reference) |
| Yes, with HiDAC (n = 132) | 0.74 (0.40-1.37); P = NS | 0.89 (0.49-1.61); P = NS | 0.89 (0.43-1.86); P = NS |
| Yes, without HiDAC (n = 39) | 0.96 (0.48-1.91); P = NS | 1.08 (0.56-2.07),;P = NS | 0.97 (0.43-2.16); P = NS |
| CR Duration before HCT (per mo) | 1.00 (0.96-1.04); P = NS | 1.01 (0.97-1.05); P = NS | 1.00 (0.95-1.05); P = NS |
| Pre-HCT karyotype | |||
| Normalized (n = 120) | 1 (reference) | 1 (reference) | 1 (reference) |
| Not normalized (n = 24) | 1.52 (0.75-3.08); P = NS | 1.25 (0.65-2.40) P = NS | 1.07 (0.47-2.42); P = NS |
| Pre-HCT blood counts† | |||
| Recovered (n = 216) | 1 (reference) | 1 (reference) | 1 (reference) |
| Not recovered (n = 36) | 0.69 (0.37-1.30); P = NS | 0.77 (0.43-1.36); P = NS | 0.71 (0.36-1.42); P = NS |
| Conditioning regimen | |||
| Without high-dose TBI (n = 181) | 1 (reference) | 1 (reference) | 1 (reference) |
| With high-dose TBI (n = 72) | 0.79 (0.42-1.48); P = NS | 0.81 (0.46-1.43); P = NS | 0.77 (0.38-1.54); P = NS |
| . | Overall mortality . | Failure for DFS . | Relapse . |
|---|---|---|---|
| MRD status | |||
| Negative (n = 199) | 1 (reference) | 1 (reference) | 1 (Reference) |
| Positive (n = 54) | 2.61 (1.62-4.20); P < .001 | 3.74 (2.38-5.87); P < .001 | 4.90 (2.87-8.37); P < .001 |
| Age (per 10 y) | 1.05 (0.90-1.22); P = NS | 1.07 (0.94-1.23); P = NS | 1.02 (0.87-1.21); P = NS |
| CR status | |||
| CR1 (n = 183) | 1 (reference) | 1 (reference) | 1 (reference) |
| CR2 (n = 70) | 1.01 (0.54-1.92); P = NS | 1.22 (0.69-2.17); P = NS | 1.15 (0.58-2.31); P = NS |
| Cytogenetic risk group | |||
| Intermediate/favorable (n = 190) | 1 (reference) | 1 (reference) | 1 (reference) |
| Adverse (n = 56) | 1.41 (0.78-2.54); P = NS | 1.50 (0.88-2.57); P = NS | 1.61 (0.83-3.13); P = NS |
| Type of AML | |||
| Primary AML (n = 184) | 1 (reference) | 1 (reference) | 1 (reference) |
| Secondary AML (n = 69) | 1.24 (0.74-2.09); P = NS | 1.29 (0.80-2.07); P = NS | 1.06 (0.59-1.92); P = NS |
| Number of induction/re-induction courses before HCT* | 1.21 (0.83-1.77); P = NS | 1.45 (1.04-2.01); P = .03 | 1.53 (1.03-2.27); P = .04 |
| Consolidation before HCT | |||
| No (n = 82) | 1 (reference) | 1 (reference) | 1 (reference) |
| Yes, with HiDAC (n = 132) | 0.74 (0.40-1.37); P = NS | 0.89 (0.49-1.61); P = NS | 0.89 (0.43-1.86); P = NS |
| Yes, without HiDAC (n = 39) | 0.96 (0.48-1.91); P = NS | 1.08 (0.56-2.07),;P = NS | 0.97 (0.43-2.16); P = NS |
| CR Duration before HCT (per mo) | 1.00 (0.96-1.04); P = NS | 1.01 (0.97-1.05); P = NS | 1.00 (0.95-1.05); P = NS |
| Pre-HCT karyotype | |||
| Normalized (n = 120) | 1 (reference) | 1 (reference) | 1 (reference) |
| Not normalized (n = 24) | 1.52 (0.75-3.08); P = NS | 1.25 (0.65-2.40) P = NS | 1.07 (0.47-2.42); P = NS |
| Pre-HCT blood counts† | |||
| Recovered (n = 216) | 1 (reference) | 1 (reference) | 1 (reference) |
| Not recovered (n = 36) | 0.69 (0.37-1.30); P = NS | 0.77 (0.43-1.36); P = NS | 0.71 (0.36-1.42); P = NS |
| Conditioning regimen | |||
| Without high-dose TBI (n = 181) | 1 (reference) | 1 (reference) | 1 (reference) |
| With high-dose TBI (n = 72) | 0.79 (0.42-1.48); P = NS | 0.81 (0.46-1.43); P = NS | 0.77 (0.38-1.54); P = NS |
Values are given as hazard ratio (95% CI), P value.
NS, not significant.
Number of induction courses for CR1 patients and number of re-induction courses for CR2 patients.
Recovered: absolute neutrophil count (ANC) ≥1000/µL and platelets ≥100 000/µL; not recovered: ANC <1000/µL and/or platelets <100 000/µL.